Terns Pharmaceuticals Inc at B Riley Securities Oncology Conference (Virtual) Transcript
Hi, good afternoon for folks on the East Coast, and good morning still for folks here on the West Coast. So, we'll get started with our next company, Terns Pharmaceutical, where we have with us, Erin Quirk, President, Head of R&D; and Mark Vignola, the CFO.
Thanks to the team and in the audience there for being part of the B. Riley oncology conference. This is Mayank Mamtani, one of the senior biotech analysts on the healthcare research team. At any point during the fireside chat, feel free to e-mail me direct questions at [email protected]. And with that out of the way, to get us started, our team really appreciate you being part of this.
I would love to hear from you sort of a high-level overview. I know the story has expanded a fair amount over the past year or so. So, I would love to have -- how sort of we think about Terns in 2023, including the focus that you have on a pipeline of clinically validated targets and sort of the development capabilities you have at a global level.
So team, please take it away.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |